Prescott S L, King B, Strong T L, Holt P G
Department of Paediatrics, University of Western Australia, Australia.
Allergy. 2003 Nov;58(11):1187-94. doi: 10.1034/j.1398-9995.2003.00263.x.
Characterizing early abnormalities in immune development of allergic individuals provides an important basis for defining disease pathogenesis and future prevention strategies. This study compares patterns of early immune responses in an established cohort based on allergic outcomes and allergen skin prick test (SPT) reactions at 6 years of age.
Children from an original birth cohort (n = 60) consisting of 44 high risk (HR) (family history of allergy) and 16 low risk (LR) (no family history) were reassessed at 6 years of age. Detailed clinical information about allergic disease was obtained (n = 53) and a subgroup (n = 31) consented to have allergen SPT to common food and inhalant allergens. Data from previous immunological assessments performed at birth, 1 and 2 years of age, including lymphoproliferation and cytokine [interleukin (IL)-4, IL-5, IL-6, IL-10, IL-13 and interferon (IFN)-gamma] responses to ovalbumin (OVA), house dust mite (HDM), cat allergen (Fel d 1), phytohaemaglutinin (PHA) and tetanus toxoid, were re-analysed based on the 6-year clinical outcomes.
Twenty-eight HR and three LR children had a clinical history of allergic disease at 6 years of age including doctor diagnosed asthma (n = 17) and/or eczema (n = 24). Most children (78%) with atopy at 6 years had positive SPT to the allergens tested, and 70% had symptoms within the last year. Children at genetic risk (family history) of allergy had weaker (P = 0.017) polyclonal T helper 1 (Th1) IFN-gamma responses in the neonatal period compared with LR children. Although children with allergic disease at 6 years also tended to have weaker neonatal IFN-gamma responses compared to those with no symptoms, but this was not quite significant (P = 0.05). A positive SPT to HDM at 6 years was associated with higher IL-13 responses to HDM at 1 year (P = 0.02), whereas allergic disease at 6 years was associated with higher IL-5 messenger RNA (mRNA) responses to HDM at 1 year (P = 0.01). Despite these associations, regression analysis demonstrated that the only significant early predictors of allergic sensitization at 6 years of age were a family history of allergic disease, and atopic symptoms at 2 years. Importantly, none of the early immunological parameters measured were significantly predictive of allergic disease or allergic sensitization in these 6-year-olds.
Although our observations suggest that subtle differential alterations in cytokine responses during early immune development are associated with different aspects of subsequent atopy, there are still no early predictive biomarkers of disease. A positive family history of allergy remains the dominant predictive factor.
明确过敏个体免疫发育的早期异常情况,可为阐释疾病发病机制及制定未来预防策略提供重要依据。本研究基于既定队列中6岁时的过敏结局及过敏原皮肤点刺试验(SPT)反应,比较早期免疫反应模式。
对原出生队列中的儿童(n = 60,其中44名高危[HR]儿童有过敏家族史,16名低危[LR]儿童无家族史)在6岁时进行重新评估。获取了有关过敏性疾病的详细临床信息(n = 53),并且一个亚组(n = 31)同意进行针对常见食物和吸入性过敏原的过敏原SPT检测。对出生时、1岁和2岁时进行的先前免疫评估数据进行重新分析,这些数据包括对卵清蛋白(OVA)、屋尘螨(HDM)、猫过敏原(Fel d 1)、植物血凝素(PHA)和破伤风类毒素的淋巴细胞增殖及细胞因子[白细胞介素(IL)-4、IL-5、IL-6、IL-10、IL-13和干扰素(IFN)-γ]反应,并依据6年的临床结局进行分析。
28名HR儿童和3名LR儿童在6岁时有过敏性疾病临床病史,包括医生诊断的哮喘(n = 17)和/或湿疹(n = 24)。6岁时大多数特应性儿童(78%)对所检测的过敏原SPT呈阳性,且其中70%在过去一年有症状。有过敏遗传风险(家族史)的儿童在新生儿期的多克隆辅助性T细胞1(Th1)IFN-γ反应比LR儿童弱(P = 0.017)。尽管6岁时有过敏性疾病的儿童与无症状儿童相比,新生儿期IFN-γ反应也往往较弱,但差异不显著(P = 0.05)。6岁时对HDM的SPT阳性与1岁时对HDM的IL-13反应较高相关(P = 0.02),而6岁时的过敏性疾病与1岁时对HDM的IL-5信使核糖核酸(mRNA)反应较高相关(P = 0.01)。尽管存在这些关联,但回归分析表明,6岁时过敏致敏的唯一显著早期预测因素是过敏性疾病家族史以及2岁时的特应性症状。重要的是,所测量的早期免疫参数均未显著预测这些6岁儿童的过敏性疾病或过敏致敏情况。
尽管我们的观察结果表明,早期免疫发育过程中细胞因子反应的细微差异改变与随后特应性的不同方面相关,但仍然没有疾病的早期预测生物标志物。过敏家族史阳性仍然是主要的预测因素。